# OmniAb Raises Revenue Outlook as Quarterly Loss Narrows

The drug-discovery technology company increased its 2026 revenue forecast to $35 million–$39 million.

By Will Langan | 24X7 News
Published: 2026-10-30T15:09:56.162Z
Updated: 2026-10-30T15:09:56.162Z
Section: Business
Format: News
Canonical: https://24x7news.us/articles/omniab-third-quarter-results-october-30-2026

OmniAb raised its annual revenue forecast October 30 while reporting higher third-quarter sales and a smaller net loss.

The company reported quarterly revenue of $4 million, compared with $2.2 million a year earlier. It attributed the increase primarily to services and sales involving its xPloration screening platform.

Net loss narrowed to $15.7 million, or 12 cents per share, from $16.5 million, or 14 cents. Total costs and operating expenses were unchanged at $20.4 million.

OmniAb now expects 2026 revenue of $35 million–$39 million, up from $32 million–$36 million. It lowered its projected costs and operating expenses to $83 million–$87 million from $84 million–$88 million.

Its year-end cash forecast increased to $53 million–$57 million from $49 million–$53 million. Cash, equivalents and short-term investments totaled $64.2 million at September 30.

For the first nine months, revenue increased to $31.8 million from $10.3 million, primarily reflecting milestone revenue. The annual figures remain forecasts; the reported financial results do not establish clinical effectiveness of partner drug candidates.

Sources: OmniAb’s October 30 financial-results announcement, Business Wire through Nasdaq.

## Sources
- OmniAb: Third-Quarter 2026 Results and Financial Guidance: https://www.nasdaq.com/press-release/omniab-reports-third-quarter-2026-financial-results-and-business-highlights-2026-10